A breakthrough in heart failure management, integrating neprilysin inhibition and angiotensin receptor blockade for optimal patient well-being.
Sacubitril/Valsartan, a new class of drug called Angiotensin Receptor Neprilysin Inhibitor (ARNI), is a US FDA-approved highly recommended treatment approach for patients with chronic heart failure. Here, Sacubitril is a neprilysin enzyme inhibitor that helps to maintain cardiovascular homeostasis and Valsartan reduces cardiac workload by reducing peripheral resistance, sodium & water retention in the body. Therefore, Sacubitril/Valsartan has transformed the treatment landscape of heart failure and widened the treatment horizon as an incredible drug of choice
Sabicard 50 Tablet: Each film coated tablet contains Sacubitril Valsartan Sodium Hemipentahydrate INN equivalent to Sacubitril 24 mg & Valsartan 26 mg.
Sabicard 100 Tablet: Each film coated tablet contains Sacubitril Valsartan Sodium Hemipentahydrate INN equivalent to Sacubitril 49 mg & Valsartan 51 mg.
Sabicard 200 Tablet: Each film coated tablet contains Sacubitril Valsartan Sodium Hemipentahydrate INN equivalent to Sacubitril 97 mg & Valsartan 103 mg.
Sabicard combination is indicated to
• Reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction.
• Sabicard is usually administered in conjunction with other heart failure therapies, in place of an ACE inhibitor or other ARB.
• The recommended starting dose of Sabicard is 100 mg twice-daily. Double the dose of Sacubitril / Valsartan after 2 to 4 weeks to the target maintenance dose of 200 mg twice-daily, as tolerated by the patient.
• Reduce the starting dose to 50 mg twice-daily for: -Patients not currently taking an angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin Il receptor blocker (ARB) or previously taking a low dose of these agents
-Patients with severe renal impairment
-Patients with moderate hepatic impairment
Double the dose of Sacubitril / Valsartan every 2 to 4 weeks to the target maintenance dose of 200 mg twice-daily, as tolerated by the patient.
Sacubitril / Valsartan is contraindicated to the following cases-
• Hypersensitivity to any component
• History of angioedema related to previous ACE inhibitor or ARB therapy
• Concomitant use of ACE inhibitors
• Concomitant use of aliskiren in patients with diabetes
• Signs and symptoms of angioedema and hypotension should be observed
• Renal function and potassium level should be monitored in susceptible patients
The most common side effects are low blood pressure, high potassium, cough, dizziness, and kidney problems. It may cause some serious side-effects like
angioedema (that may cause trouble in breathing and death) and Hyperkalemia.
Dual blockade of the renin-angiotensin system: Should not be used with an ACEI, aliskiren in patients with diabetes, and use with an ARB should be avoided
Potassium-sparing diuretics: Serum potassium level may be increased NSAIDs: Risk of renal impairment may be increased Lithium: Increased risk of lithium toxicity
Pregnancy: Can cause fetal harm when administered to a pregnant woman
Lactation: Drug should be discontinued during lactation
Pediatric use: Safety and effectiveness in pediatric patients have not been established
Geriatric use: No relevant pharmacokinetic differences have been observed in elderly (≥65 years) or very elderly (≥75 years) patients compared to the overall population.
Sabicard 50 Tablet: Each box contains 10’s tablet in Alu-Alu blister within Alu-Alu pillow pack.
Sabicard 100 Tablet: Each box contains 10’s tablet in Alu-Alu blister within Alu-Alu pillow pack.
Sabicard 200 Tablet: Each box contains 10’s tablet in Alu-Alu blister within Alu-Alu pillow pack.
FR
DE
